Yes

This debate will examine the role of circulating tumor DNA (ctDNA) testing in the adjuvant management of early-stage breast cancer outside of clinical trials. Faculty will explore the potential clinical value of ctDNA for detecting minimal residual disease, guiding treatment escalation or de-escalation and informing prognosis. The discussion will also address limitations of current evidence, assay variability, and ethical and practical considerations. Session presenters will give their expert perspective on whether and how ctDNA testing should be integrated into routine adjuvant care. Faculty will review emerging data supporting ctDNA as a tool for detecting minimal residual disease and identifying patients at higher risk for recurrence, addressing how ctDNA results may inform earlier intervention, treatment intensification, or closer surveillance. Participants will gain insight into the potential clinical utility of ctDNA testing in real-world adjuvant breast cancer care.